Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX), since the company’s rally priced a government-purchase scenario that its product line doesn’t address.

Novavax stock trades at $12.32, down 2% in morning trading. The prior session had delivered a 20% gain for Novavax shares, a figure measured through that session’s close. Meanwhile, Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $207.95, up 2%, which keeps the selling confined to one corner of the vaccine group.

The most diversified name in this vaccine cluster is inching higher as well, with Pfizer (NYSE:PFE) shares posting a muted response. Additionally, the iShares Biotechnology ETF (NASDAQ:IBB), a gauge of the wider biotech sector, is up 0.3%. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY), which tracks the broad market, is up 0.4%.

Health Officials Defuse the Siberian Plague Scare

Vaccine and biodefense shares rallied after reports that a worker at a plague research institute in Siberia had died of pneumonia of unknown origin. Traders speculated that increased preparedness could lead to government vaccine purchases, and Novavax stock was swept into that trade alongside other vaccine makers because a smaller developer such as Novavax offered the most direct exposure to that purchase narrative.

Rospotrebnadzor, the Russian public health agency, has since played down those reports. That agency stated that samples contained no microorganisms associated with the worker’s professional duties and described the regional epidemiological situation as stable. Separately, the World Health Organization asserted that the risk to the general population appeared low based on the unofficial information available to it.

Why Novavax Is Unwinding While Moderna Climbs

Those assessments removed the premise behind the spike in Novavax stock, which had rested on the idea of emergency government orders, while the company developed Nuvaxovid, a protein-based coronavirus vaccine built around its Matrix-M adjuvant, an ingredient designed to strengthen the immune response. Novavax has no plague vaccine. The pathogen in question is a bacterium, so a government stockpiling scenario tied to this case had little connection to the company’s lineup.

Moderna stock is climbing, which shows the unwind is concentrated in the most speculative corner of the vaccine group. Selling messenger RNA vaccines directly, Moderna carries the manufacturing and commercial risk that goes with its own products. Gains in Moderna stock alongside a pullback in Novavax shares suggest the market is telling a direct vaccine seller from a royalty collector.

What to Watch Next

What remains for Novavax once the scare fades is a royalty stream tied to partner sales of Nuvaxovid, plus licensing exposure through Matrix-M. Any further statement from Rospotrebnadzor or the World Health Organization is worth watching, since a change in the official assessment could revive or end the vaccine trade quickly.

Moderna stock faces its own test, because the sympathy bid behind its advance came from the same headline that lifted Novavax. The question for shareholders is whether Moderna stock holds its gains as the plague story fades from the news cycle. Pfizer shares look less exposed to that kind of reversal, given the company’s diversified business and limited reliance on any single vaccine.

Contact [email protected] for any questions or corrections.